Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 144 Cr.
- Current Price ₹ 83.8
- High / Low ₹ 154 / 52.8
- Stock P/E 13.7
- Book Value ₹ 36.3
- Dividend Yield 0.60 %
- ROCE 27.1 %
- ROE 26.3 %
- Face Value ₹ 10.0
Pros
Cons
- Company has high debtors of 188 days.
- Working capital days have increased from 102 days to 157 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 114 | 131 | |
| 85 | 104 | 114 | |
| Operating Profit | 7 | 9 | 17 |
| OPM % | 8% | 8% | 13% |
| 1 | 1 | 1 | |
| Interest | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 7 | 13 |
| Tax % | 29% | 27% | 28% |
| 3 | 5 | 10 | |
| EPS in Rs | 5.59 | ||
| Dividend Payout % | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 115% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 17 |
| Reserves | 12 | 17 | 45 |
| 19 | 26 | 25 | |
| 38 | 54 | 48 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 4 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 120 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5 | -5 | -13 | |
| -5 | -0 | 26 | |
| 1 | 5 | -4 | |
| Net Cash Flow | 1 | -0 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 128 | 159 | 188 |
| Inventory Days | 96 | 192 | 249 |
| Days Payable | 274 | 413 | 412 |
| Cash Conversion Cycle | -50 | -62 | 25 |
| Working Capital Days | 53 | 96 | 157 |
| ROCE % | 24% | 27% |
Documents
Announcements
-
Clarification - Financial Results
11 December 2024 - Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
General Updates
5 December 2024 - Zenith Drugs Limited participated in the event organized by Convention on Pharmaceutical Ingredients (CPHI), 2024.
-
Statement of deviation(s) or variation(s) under Reg. 32
14 November 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Statement of deviation(s) or variation(s) under Reg. 32
14 November 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Financial Result Updates
14 November 2024 - Zenith Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules